| Pair Name | Shikonin, Doxorubicin | ||
| Phytochemical Name | Shikonin (PubChem CID: 479503 ) | ||
| Anticancer drug Name | Doxorubicin (PubChem CID: 31703 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Shikonin, Doxorubicin | |||
| Disease Info | [ICD-11: 2B33.5] | Lymphoma | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | AKT1 | hsa207 |
| Down-regulation | Expression | MTOR | hsa2475 | |
| Down-regulation | Expression | MYC | hsa4609 | |
| Down-regulation | Expression | PIK3CA | hsa5290 | |
| In Vitro Model | Raji | EBV-related Burkitt lymphoma | Homo sapiens (Human) | CVCL_0511 |
| Namalwa | EBV-related Burkitt lymphoma | Homo sapiens (Human) | CVCL_0067 | |
| In Vivo Model | For establishment of the xenograft, a mixture of 1×10⁷ Namalwa cells and PBS was injected subcutaneously in the right oxter of each mouse. | |||
| Result | These data suggest that shikonin may be an encouraging chemotherapeutic agent in the clinical treatment of BL. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin. Sci Rep. 2018 Feb 20;8(1):3317. doi: 10.1038/s41598-018-21570-z. | Click |
